Sanctuary Advisors LLC Has $13.12 Million Stake in Kenvue Inc. (NYSE:KVUE)

Sanctuary Advisors LLC raised its stake in Kenvue Inc. (NYSE:KVUE) by 166.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 544,890 shares of the company’s stock after purchasing an additional 340,266 shares during the quarter. Sanctuary Advisors LLC’s holdings in Kenvue were worth $13,121,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Assenagon Asset Management S.A. raised its position in Kenvue by 34.9% in the 2nd quarter. Assenagon Asset Management S.A. now owns 347,625 shares of the company’s stock valued at $6,320,000 after buying an additional 89,896 shares during the last quarter. Blue Trust Inc. raised its holdings in shares of Kenvue by 20.5% in the second quarter. Blue Trust Inc. now owns 6,185 shares of the company’s stock valued at $112,000 after purchasing an additional 1,054 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. lifted its position in shares of Kenvue by 9.1% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 4,216,574 shares of the company’s stock valued at $76,657,000 after purchasing an additional 351,999 shares in the last quarter. First Horizon Advisors Inc. boosted its holdings in Kenvue by 20.4% during the second quarter. First Horizon Advisors Inc. now owns 24,093 shares of the company’s stock worth $438,000 after purchasing an additional 4,076 shares during the last quarter. Finally, Chevy Chase Trust Holdings LLC grew its position in Kenvue by 9.5% in the 2nd quarter. Chevy Chase Trust Holdings LLC now owns 1,046,754 shares of the company’s stock worth $19,030,000 after purchasing an additional 91,056 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

KVUE opened at $22.21 on Friday. The firm has a 50-day moving average price of $22.95 and a 200-day moving average price of $21.17. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $42.58 billion, a price-to-earnings ratio of 40.38, a PEG ratio of 2.02 and a beta of 1.36.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. The business had revenue of $3.90 billion during the quarter, compared to analyst estimates of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. Kenvue’s revenue was down .4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.31 EPS. Equities analysts expect that Kenvue Inc. will post 1.07 EPS for the current year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th were issued a dividend of $0.205 per share. The ex-dividend date was Wednesday, November 13th. This represents a $0.82 dividend on an annualized basis and a yield of 3.69%. Kenvue’s dividend payout ratio (DPR) is 149.09%.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Royal Bank of Canada upgraded Kenvue from a “hold” rating to a “moderate buy” rating in a research note on Monday, December 9th. JPMorgan Chase & Co. upped their price objective on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Barclays upgraded Kenvue to a “hold” rating in a research note on Thursday. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and reduced their price target for the company from $25.00 to $24.00 in a research report on Thursday. Finally, Bank of America lifted their price objective on shares of Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, October 22nd. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, Kenvue has a consensus rating of “Hold” and an average price target of $22.64.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.